Treatment of multiple myeloma. High-dose intermittent administration of cyclophosphamide and prednisolone--follow up study of 10 years period
Mizuno, H.; Ninomiya, N.; Ohta, H.; Tokoro, K.; Yasuma, A.; Ohnishi, K.; Ikeda, Y.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 10(11): 2286-2291
1983
ISSN/ISBN: 0385-0684 PMID: 6639091 Document Number: 206887
Twenty patients with plasma cell myeloma were treated with high-dose (10 mg/kg) intermittent administration of cyclophosphamide for remission induction and maintenance therapy. High-dose intermittent administration of glucocorticosteroid hormone was also performed usually in parallel with large-dose of cyclophosphamide. A significant objective response was obtained in 12 of 20 patients (60.0%). The median survival was 32 months in all cases; 47 months in the responding cases. The response rate was not affected by the class of M-protein, the type of light-chain and/or the presence of bone lesions. All responders were on the 3rd stage. High-dose intermittent administration of cyclophosphamide was evaluated as very useful since it showed equivalent effects obtained by combination chemotherapy regimens, hardly producing bone marrow suppression.